CN111065413A - TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 - Google Patents
TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 Download PDFInfo
- Publication number
- CN111065413A CN111065413A CN201980002739.7A CN201980002739A CN111065413A CN 111065413 A CN111065413 A CN 111065413A CN 201980002739 A CN201980002739 A CN 201980002739A CN 111065413 A CN111065413 A CN 111065413A
- Authority
- CN
- China
- Prior art keywords
- taci
- fusion protein
- neuromyelitis optica
- days
- nmosd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于B淋巴细胞刺激因子受体‑抗体融合蛋白治疗自身免疫性疾病的领域,具体是TACI‑Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病(NMOSD)和多发性硬化(MS)的药物。
Description
PCT国内申请，说明书已公开。
Claims (7)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810512508.8A CN110522908A (zh) | 2018-05-25 | 2018-05-25 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| CN2018105125088 | 2018-05-25 | ||
| PCT/CN2019/086990 WO2019223581A1 (zh) | 2018-05-25 | 2019-05-15 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111065413A true CN111065413A (zh) | 2020-04-24 |
Family
ID=68616227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810512508.8A Withdrawn CN110522908A (zh) | 2018-05-25 | 2018-05-25 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| CN201980002739.7A Withdrawn CN111065413A (zh) | 2018-05-25 | 2019-05-15 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810512508.8A Withdrawn CN110522908A (zh) | 2018-05-25 | 2018-05-25 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210087253A1 (zh) |
| CN (2) | CN110522908A (zh) |
| TW (1) | TW202011990A (zh) |
| WO (1) | WO2019223581A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025458A2 (pt) * | 2019-12-10 | 2022-06-21 | Remegen Co Ltd | Formulação farmacêutica, método de preparação e uso da mesma |
| JP2022539785A (ja) * | 2019-12-24 | 2022-09-13 | レメゲン シーオー．，エルティーディー． | ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途 |
| EP4146683A1 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| US20240018212A1 (en) * | 2021-09-30 | 2024-01-18 | RemeGen Co., Ltd | Method for treating sjogren's syndrome using taci-fc fusion protein |
| AU2023283931A1 (en) * | 2022-06-08 | 2024-05-16 | Remegen Co., Ltd. | Method for treating myasthenia gravis with taci-fc fusion protein |
| WO2024120458A1 (zh) * | 2022-12-07 | 2024-06-13 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白液体药物制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101323643B (zh) * | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
| EP2219675B1 (en) * | 2007-11-12 | 2013-10-23 | Ares Trading S.A. | Formulations for taci-immunoglobulin fusion proteins |
-
2018
- 2018-05-25 CN CN201810512508.8A patent/CN110522908A/zh not_active Withdrawn
-
2019
- 2019-05-15 US US16/760,413 patent/US20210087253A1/en not_active Abandoned
- 2019-05-15 WO PCT/CN2019/086990 patent/WO2019223581A1/zh active Application Filing
- 2019-05-15 CN CN201980002739.7A patent/CN111065413A/zh not_active Withdrawn
- 2019-05-21 TW TW108117457A patent/TW202011990A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110522908A (zh) | 2019-12-03 |
| US20210087253A1 (en) | 2021-03-25 |
| TW202011990A (zh) | 2020-04-01 |
| WO2019223581A1 (zh) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065413A (zh) | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 | |
| Tsang et al. | Multiple sclerosis: diagnosis, management and prognosis | |
| AU2020204023A1 (en) | Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders | |
| US8298525B2 (en) | Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist | |
| CN105188751A (zh) | 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 | |
| WO2013022882A1 (en) | Combination therapy for treatment of inflammatory demyelinating disease | |
| CN113286604B (zh) | 治疗炎症性疾病的蛋白质 | |
| DK3099307T3 (en) | Use of cladribine for the treatment of neuromyelitis optica | |
| WO2021128027A1 (zh) | TACI-Fc融合蛋白及其用途 | |
| JP2023542878A (ja) | 多発性硬化症を治療するためのｌｏｕ０６４ | |
| Nicotera et al. | Treatment of multiple sclerosis in children: A brief overview | |
| WO2011131705A1 (en) | Treatment of multiple sclerosis with masitinib | |
| CN114375306A (zh) | 奥法木单抗治疗患者中除多发性硬化症以外病症的管理 | |
| EP2032151A2 (en) | Combination therapy method and formulation | |
| Caponnettoa et al. | Mycophenolate Mofetil: A New Immunosuppressive Approach | |
| KR20220166827A (ko) | 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙 | |
| CN114401742A (zh) | 通过转换疗法治疗rms | |
| MacLean et al. | Immunologic therapy for relapsing-remitting multiple sclerosis | |
| US12030950B2 (en) | Treatment of multiple sclerosis and neuromyelitis optica | |
| US20200017597A1 (en) | Treatment of multiple sclerosis and neuromyelitis optica | |
| US20130108617A1 (en) | Plasma-derived immunoglobulin for use in the treatment and prevention of immune reconstitution inflammatory syndrome (iris) | |
| KR20230170923A (ko) | 아시아인 환자들에서 ms 치료용 오파투무맙 | |
| JP2024509911A (ja) | 疾患の治療のための方法及び組成物 | |
| Hohlfeld | IMMUNE MECHANISMS IN RELATION TO THERAPY | |
| EP4395779A1 (en) | Lou064 for treating multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information |
Address after: 264006 China (Shandong) pilot Free Trade Zone, Yantai City, Shandong Province Applicant after: Rongchang biopharmaceutical (Yantai) Co., Ltd Address before: 264006 Yantai economic and Technological Development Zone, Beijing, No. 58 Middle Road, Shandong Applicant before: Rongchang biopharmaceutical (Yantai) Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200424 |
|
| WW01 | Invention patent application withdrawn after publication |